Data View: Medicaid Spending and Utilization for Central Nervous System Drugs

Prior research has shown that prescription drug spending grew substantially during the decade of the 1990s. This analysis uses 1996 to 1998 State Medicaid Research File (SMRF) fee-for-service (FFS) data for 29 participating States to provide insight into the factors driving this growth. The analysis...

Full description

Saved in:
Bibliographic Details
Published inHealth care financing review Vol. 26; no. 1; pp. 57 - 73
Main Authors Baugh, David K., Pine, Penelope L., Blackwell, Steve, Ciborowski, Gary
Format Journal Article
LanguageEnglish
Published CENTERS for MEDICARE & MEDICAID SERVICES 01.01.2004
Online AccessGet full text

Cover

More Information
Summary:Prior research has shown that prescription drug spending grew substantially during the decade of the 1990s. This analysis uses 1996 to 1998 State Medicaid Research File (SMRF) fee-for-service (FFS) data for 29 participating States to provide insight into the factors driving this growth. The analysis examines cost variation by census region, State, Medicaid basis of eligibility, and therapeutic use of drugs. In 1998, the highest expenditures were for central nervous system (CNS) drugs and for anti-psychotics compared to three other groups of CNS drugs (anti-anxiety agents, anti-depressants, and hypnotics). By eligibility group, expenditures were typically highest for disabled enrollees. There were major variations among SMRF States and their respective regions.
ISSN:0195-8631
1554-9887